Oncology Meeting Resources

In this section, you can find all available abstracts, presentations and webcasts on OncologyPRO.

Here below, you can search across all meeting resources by session title, presentation title, presenter or keyword. Results can then be refined by topic, event and publication date.

The use of these presentations is for personal educational purposes only.
ESMO thanks the authors for their generosity.




Format available

https://oncologypro.esmo.org/Meeting-Resour...ies-Congress-2019/Proffered-Paper-session-22

CC-90011 is a potent, selective, reversible oral inhibitor of the epigenetic target, lysine-specific demethylase 1A (LSD1) that has demonstrated anti-proliferative activity against cancer cells in vitro...

Date: 26 Feb 2019
Presenter: Antoine Hollebecque
Resources: Abstract, Presentation, Webcast
Topic: Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...19/Case-presentation-on-non-Hodgkin-Lymphoma

Date: 16 Feb 2019
Presenter: A. Nyakabau, ZW
Resources: Presentation
Topic: Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...e-changing-studies-on-non-Hodgkin-s-Lymphoma

Date: 16 Feb 2019
Presenter: C. Buske, DE
Resources: Presentation
Topics: Lymphomas, Anticancer Agents

https://oncologypro.esmo.org/Meeting-Resour...2019/Case-presentation-on-Hodgkin-s-Lymphoma

Date: 16 Feb 2019
Presenter: S. Viranna, ZA
Resources: Presentation
Topic: Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...rent-standards-of-care-of-Hodgkin-s-Lymphoma

Date: 16 Feb 2019
Presenter: C. Buske, DE
Resources: Presentation
Topic: Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...t-HSCT-DLBCL-Relapse-Responding-to-Nivolumab

Date: 18 Jan 2019
Presenter: I. Madabhavi, IN
Resources: Presentation
Topics: Immunotherapy, Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...mphoma-and-Other-Haematological-Malignancies

Date: 18 Jan 2019
Presenter: S. T. Lim, SG
Resources: Presentation
Topics: Immunotherapy, Lymphomas

https://oncologypro.esmo.org/Meeting-Resour...osed-primary-central-nervous-system-lymphoma

BackgroundThe treatment of primary CNS lymphoma (PCNSL) comprises high dose Methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy(WBRT), the major drawback of which is long term neurotoxicity.

Date: 24 Nov 2018
Presenter: Narayan Adhikari
Resources: Abstract
Topics: Lymphomas, Radiation Oncology, Central Nervous System Malignancies

https://oncologypro.esmo.org/Meeting-Resour...-CD20-Positive-Diffuse-Large-B-Cell-Lymphoma

BackgroundWhile rituximab (rituximab) has revolutionized the treatment of B-cell lymphoma (BCL), its high manufacturing cost and lack of lower-priced competition have driven up prices resulting in...

Date: 24 Nov 2018
Presenter: Yuankai Shi
Resources: Abstract
Topics: Anticancer Agents, Lymphomas, Clinical Research

https://oncologypro.esmo.org/Meeting-Resour...rrelation-with-tumor-transcriptomic-profiles

BackgroundExtranodal NK/T-cell lymphoma, nasal type (NKTCL) is an aggressive Epstein-Barr Virus-associated lymphoproliferative malignancy typified by local immune cell infiltration and variable states of systemic inflammation.

Date: 24 Nov 2018
Presenter: Tan Khee Ming
Resources: Abstract
Topics: Lymphomas, Pathology/Molecular Biology